The prophylactic use of low-dose amphotericin B in bone marrow transplant patients
Authors:
- Andrew T. PaviaAPAndrew T. Pavia
- Patrick G. BeattyPBPatrick G. Beatty
- Finn B. PetersenFPFinn B. Petersen
- Joanne L. SpruanceJSJoanne L. Spruance
- Ron StokesRSRon Stokes
- Thomas G. EvansTEThomas G. Evans
- 1 December 1994
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 97 (6) , 509-514
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Prophylactic Intravenous Amphotericin B in Neutropenic Autologous Bone Marrow Transplant RecipientsThe Journal of Infectious Diseases, 1992
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992
- Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantationThe American Journal of Medicine, 1991
- Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with FluconazoleNew England Journal of Medicine, 1991
- Amphotericin B: current understanding of mechanisms of actionAntimicrobial Agents and Chemotherapy, 1990
- Studies on the molecular mechanisms of human Fc receptor-mediated phagocytosis. Amplification of ingestion is dependent on the generation of reactive oxygen metabolites and is deficient in polymorphonuclear leukocytes from patients with chronic granulomatous disease.Journal of Clinical Investigation, 1988
- Prevention of Mycoses in Immunocompromised PatientsClinical Infectious Diseases, 1987
- Comparative Trial of Ketoconazole and Nystatin for Prevention of Fungal Infection in Neutropenic Patients Treated in a Protective EnvironmentThe Journal of Infectious Diseases, 1985
- KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTSThe Lancet, 1982